Astrazeneca Plc Stock Cash Per Share
| AZNCF Stock | USD 125.50 0.80 0.64% |
AstraZeneca PLC fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Pink Sheet. The fundamental analysis module provides a way to measure AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AstraZeneca PLC pink sheet.
AstraZeneca |
AstraZeneca PLC Company Cash Per Share Analysis
AstraZeneca PLC's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current AstraZeneca PLC Cash Per Share | 3.15 X |
Most of AstraZeneca PLC's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, AstraZeneca PLC has a Cash Per Share of 3.15 times. This is 27.59% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The cash per share for all United States stocks is 37.13% higher than that of the company.
AstraZeneca Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AstraZeneca PLC's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics of similar companies.AstraZeneca PLC is currently under evaluation in cash per share category among its peers.
AstraZeneca Fundamentals
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 241.1 B | |||
| Shares Outstanding | 1.55 B | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 48.84 % | |||
| Price To Earning | 44.18 X | |||
| Price To Book | 6.16 X | |||
| Price To Sales | 4.73 X | |||
| Revenue | 44.35 B | |||
| Gross Profit | 35.73 B | |||
| EBITDA | 9.33 B | |||
| Net Income | 3.29 B | |||
| Cash And Equivalents | 4.89 B | |||
| Cash Per Share | 3.15 X | |||
| Total Debt | 22.96 B | |||
| Debt To Equity | 0.87 % | |||
| Current Ratio | 0.96 X | |||
| Book Value Per Share | 23.91 X | |||
| Cash Flow From Operations | 9.81 B | |||
| Earnings Per Share | 2.11 X | |||
| Price To Earnings To Growth | 1.37 X | |||
| Number Of Employees | 42 | |||
| Beta | 0.19 | |||
| Market Capitalization | 215.86 B | |||
| Total Asset | 96.48 B | |||
| Retained Earnings | 6.38 B | |||
| Working Capital | (2.52 B) | |||
| Current Asset | 12.87 B | |||
| Current Liabilities | 15.38 B | |||
| Z Score | 5.4 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 3.01 % | |||
| Net Asset | 96.48 B | |||
| Last Dividend Paid | 2.9 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in AstraZeneca Pink Sheet
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.